Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
Brief Summary:
This is a prospective study evaluating the activity and the safety of toremifene in patients with primary or recurrent sporadic DTs.
Patients will be enrolled after the histological confirmation of DTs on biopsy Patients will start at 60 mg daily and dose-escalate to 180 mg upon progression. Disease assessment will be performed by contrast-enhanced MRI or CT scan, pain evaluation by a visual analog scale (VAS) every 3 months for the first and second year, twice yearly thereafter. Response will be evaluated either by RECIST and/or symptomatic relief.